BioXcel Therapeutics (BTAI) Tops Q3 EPS by 8c

BioXcel Therapeutics (NASDAQ: BTAI) reported Q3 EPS of ($0.57), $0.08 better than the analyst estimate of ($0.65).

“We are pleased with the progress made on both of our clinical development programs during the quarter,” stated Vimal Mehta, Chief Executive Officer of BTAI. “BXCL501, our candidate for the acute treatment of agitation in patients with schizophrenia and bipolar disease and delivered in a sublingual thin film, is highly differentiated from the current standards of care, which can produce unwanted side effects and be difficult for caregivers to administer. BXCL501 has the potential to significantly improve care for patients, while providing healthcare providers with an important new option for treating their patients. We’re looking forward to reporting pivotal data during the first half of 2020.”

Dr. Mehta added, “We are also pleased with the progress of our Phase 1b/2 double combination study of BXCL701 and Keytruda for tNEPC and anticipate additional safety data readouts from both cohorts in the fourth quarter of this year, followed by expected initial efficacy data in the first half of 2020.”

For earnings history and earnings-related data on BioXcel Therapeutics (BTAI) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Z Squared outlines AI power strategy and Paradox Data acquisition
• Reading (RDI) Tops Q2 EPS by 4c